Systemic and barrier contraceptives for the dermatologist: a review
2009; Wiley; Volume: 48; Issue: 8 Linguagem: Inglês
10.1111/j.1365-4632.2009.04148.x
ISSN1365-4632
AutoresC. Stanley Chan, Mandy Harting, Ted Rosén,
Tópico(s)Diversity and Career in Medicine
ResumoInternational Journal of DermatologyVolume 48, Issue 8 p. 795-814 Systemic and barrier contraceptives for the dermatologist: a review C. Stanley Chan MD, C. Stanley Chan MD From the Department of Dermatology, Baylor College of Medicine, Houston, TexasSearch for more papers by this authorMandy Harting MD, Mandy Harting MD Present address: Department of Dermatology, University of Michigan, Ann Arbor, MichiganSearch for more papers by this authorTed Rosen MD, Ted Rosen MD From the Department of Dermatology, Baylor College of Medicine, Houston, TexasSearch for more papers by this author C. Stanley Chan MD, C. Stanley Chan MD From the Department of Dermatology, Baylor College of Medicine, Houston, TexasSearch for more papers by this authorMandy Harting MD, Mandy Harting MD Present address: Department of Dermatology, University of Michigan, Ann Arbor, MichiganSearch for more papers by this authorTed Rosen MD, Ted Rosen MD From the Department of Dermatology, Baylor College of Medicine, Houston, TexasSearch for more papers by this author First published: 20 July 2009 https://doi.org/10.1111/j.1365-4632.2009.04148.xCitations: 2 Ted Rosen, MD 2815 Plumb Houston TX 77005 E-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Mitchell AA. Teratogens and the dermatologist. New knowledge, responsibilities, and opportunities. Arch Dermatol 1991; 127: 399– 401. 2 Lammer EJ, Chen DT, Hoar RM, et al . Retinoic acid embryopathy. N Engl J Med 1985; 313: 837– 841. 3 Warkany J. Teratogenicity of folic acid antagonists. Cancer Bull 1981; 33: 76– 77. 4 Kowal D. Coitus interruptus (withdrawal). In: RA Hatcher, J Trussell, F Stewart, et al . eds. Contraceptive Technology, 18th revised edn. New York, NY: Ardent Media, 2004. 5 Zukerman Z, Weiss DB, Orvieto R. Does preejaculatory penile secretion originating from Cowper's gland contain sperm? J Assist Reprod Genet 2003; 20: 157– 159. 6 Researchers find no sperm in pre-ejaculate fluid. Contracept Technol Update 1993; 14: 154– 156 [abstract]. 7 Wilcox AJ, Weinberg CR, Baird DD. Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy, and sex of the baby. N Engl J Med 1995; 333: 1517– 1521. 8 Abma JC, Chandra A, Mosher WD, et al . Fertility, family planning, and women's health: new data from the 1995 National Survey of Family Growth. Vital Health Stat 23 1997; 19: 1– 114. 9 Moran JS, Janes HR, Peterman TA, et al . Increase in condom sales following AIDS education and publicity, United States. Am J Public Health 1990; 80: 607– 608. 10 Cates W Jr. Review of non-hormonal contraception (condoms, intrauterine devices, nonoxynol-9 and combos) on HIV acquisition. J Acquir Immune Defic Syndr 2005; 38(Suppl. 1): S8– S10. 11 Gallo MF, Grimes DA, Schulz KF. Non-latex versus latex male condoms for contraception. Cochrane Database Syst Rev 2003; 2: CD003550. 12 Rosen AD, Rosen T. Study of condom integrity after brief exposure to over-the-counter vaginal preparations. South Med J 1999; 92: 305– 307. 13 Warner L, Steiner MJ. Condom access does not ensure condom use: you've got to be putting me on. Sex Transm Infect 2002; 78: 225. 14 Hoffman S, Mantell J, Exner T, et al . The future of the female condom. Perspect Sex Reprod Health 2004; 36: 120– 126. 15 Trussell J, Sturgen K, Strickler J, et al . Comparative contraceptive efficacy of the female condom and other barrier methods. Fam Plann Perspect 1994; 26: 66– 72. 16 Joanis C, Latka M, Glover LH, et al . Structural integrity of the female condom after a single use, washing, and disinfection. Contraception 2000; 62: 63– 72. 17 Beksinska ME, Rees HV, Dickson-Tetteh KE, et al . Structural integrity of the female condom after multiple uses, washing, drying, and re-lubrication. Contraception 2001; 63: 33– 36. 18 Minnis AM, Padian NS. Effectiveness of female controlled barrier methods in preventing sexually transmitted infections and HIV: current evidence and future research directions. Sex Transm Infect 2005; 81: 193– 200. 19 Harvey SM, Bird ST, Branch MR. A new look at an old method: the diaphragm. Perspect Sex Reprod Health 2003; 35: 270– 273. 20 Herndon EJ, Zieman M. New contraceptive options. Am Fam Physician 2004; 69: 853– 860. 21 Schwartz B, Gaventa S, Broome CV, et al . Nonmenstrual toxic shock syndrome associated with barrier contraceptives: report of a case–control study. Rev Infect Dis 1989; 11(Suppl. 1): S43– S48. 22 Cook L, Nanda K, Grimes DA. Diaphragm versus diaphragm with spermicides for contraception. Cochrane Database Syst Rev 2003; (1): CD002031. 23 Parazzini F, Negri E, La Vecchia C, et al . Barrier methods of contraception and the risk of cervical neoplasia. Contraception 1989; 40: 519– 530. 24 Hsieh CY, You SL, Kao CL, et al . Reproductive and infectious risk factors for invasive cervical cancer in Taiwan. Anticancer Res 1999; 19: 4495– 4500. 25 Fihn SD, Latham RH, Roberts P, et al . Association between diaphragm use and urinary tract infection. J Am Med Assoc 1985; 254: 240– 245. 26 Allen RE. Diaphragm fitting. Am Fam Physician 2004; 69: 97– 100. 27 10 years out: cervical cap overcoming barriers. Contracept Technol Update 1998; 19: 148– 149. 28 Weiss BD, Bassford T, Davis T. The cervical cap. Am Fam Physician 1991; 43: 517– 523. 29 Cates W, Raymond EG. Vaginal spermicides. In: Hatcher RA, Trussell J, Stewart F, et al . Contraceptive Technology, 18th revised edn. New York, NY: Ardent Media, 2004. 30 Wilkinson D, Ramjee G, Tholandi M, et al . Nonoxynol-9 for preventing vaginal acquisition of HIV infection by women from men. Cochrane Database Syst Rev 2002; (4): CD003936. 31 United Nations. World Contraceptive Use 2003. New York: United Nations Department of Economic and Social Affairs, Population Division, 2004. 32 Hormones, Oral Contraceptives. In Threlkeld DS. Facts and Comparisons Drug Information. St. Louis, Missouri: Lippincott, Williams and Wilkins, 1999, pages 107b– Bf. 33 Frye CA. An overview of oral contraceptives: mechanism of action and clinical use. Neurology 2006; 66: S29– S36. 34 Petitti DB. Combination estrogen–progestin oral contraceptives. N Engl J Med 2003; 349: 1443– 1450. 35 Cedars MI. Triphasic oral contraceptives: review and comparison of various regimens. Fertil Steril 2002; 77: 1– 14. 36 Dunson TR, McLaurin VL, Aguayo EL, et al . A multicenter comparative trial of triphasic and monophasic, low-dose combined oral contraceptives. Contraception 1993; 47: 515– 525. 37 Cerel-Suhl SL, Yeager BF. Update on oral contraceptive pills. Am Fam Physician 1999; 60: 2073– 2084. 38 Rosenberg MJ, Waugh MS, Burnhill MS. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect 1998; 30: 104. 39 Apelo RA, Suplido A. Clinical assessment of a new triphasic oral contraceptive. Clin Ther 1985; 8: 61– 70. 40 Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception 1999; 60: 321– 329. 41 Sanders SA, Graham CA, Bass JL, Bancroft J. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception 2001; 64: 51– 58. 42 Oinonen KA, Mazmanian D. To what extent do oral contraceptives influence mood and affect? J Affect Disord 2002; 70: 229– 240. 43 Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000; 61: 105– 111. 44 Rosenberg M. Weight change with oral contraceptive use and during the menstrual cycle. Results of daily measurements. Contraception 1998; 58: 345– 349. 45 Gallo MF, Lopez LM, Grimes DA, et al . Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2003; (2): CD003987. 46 Tanis BC, Van Den Bosch MA, Kemmeren JM, et al . Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001; 345: 1787– 1793. 47 Khader YS, Rice J, John L, Abueita O. Oral contraceptive use and the risk of myocardial infarction: a meta-analysis. Contraception 2003; 68: 11– 17. 48 Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners’ oral contraception study. Br Med J 1989; 298: 165– 168. 49 Lidegaard O, Kreiner S. Contraceptives and cerebral thrombosis: a five year national case–control study. Contraception 2002; 65: 197– 205. 50 Chang CL, Donaghy M, Poulter N. Migraine and stroke in young women: case–control study. The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Br Med J 1999; 318: 13– 18. 51 Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,237 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713– 1727. 52 Vessey M, Painter R. Oral contraceptive use and cancer. Findings from a large cohort study, 1968–2004. Br J Cancer 2006; 95: 385– 389. 53 Marchbanks PA, McDonald JA, Wilson HG, et al . Oral contraceptives and the risk of breast cancer. N Engl J Med 2002; 346: 2025– 2032. 54 The use of hormonal contraception in women with coexisting medical conditions. ACOG Practice Bulletin no. 18. Int J Gynecol Obstet 2001; 75: 93– 106. 55 World Health Organization. Medical Eligibility Criteria. URL http://www.who.int/reproductive-health/publications/mec/3_cocs.pdf [accessed on 17 April 2006]. 56 Stang A, Schwingl P, Rivera R. New contraceptive eligibility checklists for provision of combined oral contraceptives and depot-medroxyprogesterone acetate in community-based programmes. Bull World Health Org 2000; 78: 1015– 1023. URL http://whqlibdoc.who.int/bulletin/2000/Number%208/78 (8)1015-1023pdf [accessed on 17 April 2006]. 57 Darney PD. The androgenicity of progestins. Am J Med 1995; 98: 1A– 104S. 58 Jones EE, Androgenic effects of oral contraceptives: implications for patient compliance. Am J Med 1995; 98(Suppl. 1A): 116S– 119S. 59 Olson WH, Lippman JS, Robisch DM. The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris. Int J Fertil Womens Med 1998; 43: 286– 290 [abstract]. 60 Rosen MP, Breitkopf DM, Nagamani M. A randomized controlled trial of second- versus third-generation oral contraceptives in the treatment of acne vulgaris. Am J Obstet Gynecol 2003; 188: 1158– 1160. 61 Leyden J, Shalita A, Hordinsky M, et al . Efficacy of a low-dose oral contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for the treatment of moderate acne: a randomized, placebo-controlled trial. J Am Acad Dermatol 2002; 47: 399– 409. 62 James WD. Clinical practice. Acne. N Engl J Med 2005; 352: 1463– 1472. 63 Van Vloten WA, Sigurdsson V. Selecting an oral contraceptive agent for the treatment of acne in women. Am J Clin Dermatol 2004; 5: 435– 441. 64 Milsom I, Sundell G, Andersh B. The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea. Contraception 1990; 42: ?hangover 0>497– 506. 65 Mishell DR Jr. Noncontraceptive health benefits of oral steroidal contraceptives. Am J Obstet Gynecol 1982; 142: 809– 816. 66 Nillson L, Rybo G. Treatment of menorrhagia. Am J Obstet Gynecol 1971; 110: 713– 720. 67 Runnenbaum B, Grunwald K, Rabe T. The efficacy and tolerability of norgestimate/ethinyl estradiol: results of an open, multicenter study of 59,701 women. Am J Obstet Gynecol 1992; 166: 1963– 1968. 68 Task Force for Epidemiological Research on Reproductive Health, United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank Special Programme of Research Development, Research Training in Human Reproduction, World Health Organization, Geneva, Switzerland. Effects of contraceptives on hemoglobin and ferritin. Contraception 1998; 58: 262– 273. 69 Kuohung W, Borgatta L, Stubblefield P. Low-dose oral contraceptives and bone mineral density: an evidence-based analysis. Contraception 2000; 61: 77– 82. 70 The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral contraceptive use. N Engl J Med 1987; 316: 650– 655. 71 The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. Combination oral contraceptive use and the risk of endometrial cancer. J Am Med Assoc 1987; 257: 796– 800. 72 Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Stewart F, et al . Contraceptive Technology, 18th revised edn. New York, NY: Ardent Media, 2004. 73 Trussel J. Contraceptive efficacy. Arch Dermatol 1995; 131: 1064– 1068. 74 Gallo MF, Grimes DA, Schulz KF, et al . 20 mcg versus > 20 mcg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev 2004; (4): CD003989. 75 Skolnick JL, Stoler BS, Katz DB, et al . Rifampin, oral contraceptives, and pregnancy. J Am Med Assoc 1976; 236: 1382. 76 Robertson YR, Johnson ES. Interactions between oral contraceptives and other drugs: a review. Curr Med Res Opin 1976; 3: 647– 661. 77 Back DJ, Breckenridge AM, Crawford F, et al . The effect of rifampicin on the pharmokinetics of ethynylestradiol in women. Contraception 1980; 21: 135– 143. 78 Nocke-Finck L, Breuer H, Reimers D. Effects of rifampin on menstrual cycle and on estrogen excretion in patients taking oral contraceptives. Dtsch Med Wochenschr 1973; 98: 1521– 1523. 79 Dosseter J. Drug interactions with oral contraceptives [letter]. Br Med J 1975; 4: 467– 468. 80 Bacon JF, Shenfield GM. Pregnancy attributable to interaction between tetracycline and oral contraceptives. Br Med J 1980; 280: 93. 81 DeSano EA, Hurley SC. Possible interactions of antihistamines and antibiotics with oral contraceptives effectiveness. Fertil Steril 1982; 37: 853– 854. 82 Hughes BR, Cunliffe WJ. Interactions between the oral contraceptive pill and antibiotics [letter]. Br J Dermatol 1990; 122: 717– 718. 83 Physicians’ Desk Reference Electronic Library. Montvale, NJ. Thomson PDR, 2005. 84 Dickinson BD, Altman RD, Nielsen NH, et al . Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol 2001; 98: 853– 860. 85 Archer JS, Archer DF. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol 2002; 46: 917– 923. 86 King VJ. OC failure rates and oral antibiotics. J Fam Pract 1997; 45: 104– 105. 87 Helms SE, Bredle DL, Zajic J, et al . Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol 1997; 36: 705– 710. 88 Weisberg E. Interactions between oral contraceptives and antifungals/antibacterials. Is contraceptive failure the result? Clin Pharmacokinet 1999; 36: 309– 313. 89 Brody SA, Turkes A, Goldzieher JW. Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 µg and three norethindrone/ethinyl estradiol-35 µg OC formulations: are “low dose” pills really lower? Contraception 1989; 40: 269– 284. 90 Back DJ, Breckenridge AM, Crawford FE, et al . Interindividual variation and drug interactions with hormonal steroid contraceptives. Drugs 1981; 21: 46– 61. 91 Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003; 68: 89– 96. 92 Den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 1999; 59: 357– 362. 93 NuvaRing® Package Insert. Roseland, NJ: Organon Pharmaceuticals USA, Inc., 2005. 94 Alexander NJ, Baker E, Kaptein M, et al . Why consider vaginal drug administration? Fertil Steril 2004; 82: 1– 12. 95 Van Den Heuvel MW, Van Bragt AJM, Alnabawy AKM, et al . Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005; 72: 168– 174. 96 Oddsson K, Leifels-Fischer B, De Melo NR, et al . Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 2005; 71: 176– 182. 97 Roumen F. Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing. Eur J Contracept Reprod Health Care 2002; 7(Suppl. 2): 19– 24 [abstract]. 98 Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002; 100: 585– 593. 99 Novak A, De La Loge C, Abetz L, et al . The combined contraceptive vaginal ring, NuvaRing: an international study of user acceptability. Contraception 2003; 67: 187– 194. 100 Sicat BL. Ortho Evra, a new contraceptive patch. Pharmacotherapy 2003; 23: 472– 480. 101 Potter L, Oakley D, De Leon-Wong E, et al . Measuring compliance among oral contraceptive users. Fam Plann Perspect 1996; 28: 154– 158. 102 Zieman M, Guillebaud J, Weisberg E, et al . Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002; 77: S13– S18. 103 Burkman RT. The transdermal contraceptive system. Am J Obstet Gynecol 2004; 190: S49– S53. 104 Goa KL, Warner GT, Easthope SE. Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonal contraception. Treat Endocrinol 2003; 2: 191– 206. 105 Ortho Evra (Norelgestromin/Ethinyl Estradiol Transdermal System) Package Insert. Raritan, NJ: Ortho-McNeil Pharmaceutical Inc., 2001. 106 Hatcher RA. Depo-provera, injections, implants, and minipills. In: Hatcher RA, Trussell J, Stewart F, et al . Contraceptive Technology, 18th revised edn. New York, NY: Ardent Media, 2004. 107 Forinash AB, Evans SL. New hormonal contraceptives: a comprehensive review of the literature. Pharmacotherapy 2003; 23: 1573– 1591. 108 Zacur HA, Hedon B, Mansour D, et al . Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. Fertil Steril 2002; 77: S32– S35. 109 New warning on birth control patch. FDA Consum 2006; 40(1): 4. URL http://www.fda.gov/bbs/topics/news/2005/NEW01262html [accessed on 10 May 2006]. 110 Croxatto HB. Mechanisms that explain the contraceptive action of progestin implants for women. Contraception 2002; 65: 21– 27. 111 Lidegaard O. Oral contraception and risk of a cerebral thromboembolic attack: results of a case–control study. Br Med J 1993; 306: 956– 963. 112 World Health Organization. Medical Eligibility Criteria for Contraceptive Use, 3rd edn. 2004. URL http://www.who.int/reproductive-health/publications/mec/cocs.html [accessed on 27 April 2006]. 113 Apgar BS, Greenberg G. Using progestins in clinical practice. Am Fam Physician 2000; 62: 1849– 1850. 114 Chi IC. The progestin-only pills and the levonorgestrel-releasing IUD: two progestin-only contraceptives. Clin Obstet Gynecol 1995; 38: 872– 889 [abstract]. 115 Westhoff C. Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety. Contraception 2003; 68: 75– 87. 116 Breast cancer and depot-medroxyprogesterone acetate: a multinational study. WHO collaborative study of neoplasia and steroid contraceptives. Lancet 1991; 338: 833– 838. 117 Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO collaborative study of neoplasia and steroid contraceptives. Int J Cancer 1991; 49: 182– 185. 118 Hatcher RA, Schnare S. Ask the experts: progestin-only contraceptives. Contracept Technol Update 1993; 14: 114– 115. 119 Matson SC, Henderson KA, McGrath GJ. Physical findings and symptoms of depot medroxyprogesterone acetate use in adolescent females. J Pediatr Adolesc Gynecol 1997; 10: 18– 23. 120 Curtis KM, Martins SL. Progestogen-only contraception and bone mineral density: a systematic review. Contraception 2006; 73: 470– 487 [abstract]. 121 Westhoff C. Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes. J Reprod Med 1996; 41: 401– 406. 122 Khoiny FE. Use of depo-provera in teens. J Pediatr Health Care 1996; 10: 195– 201. 123 Glasier A. Implantable contraceptives for women: effectiveness, discontinuation rates, return of fertility, and outcome of pregnancies. Contraception 2002; 65: 29– 37. 124 Harrison-Woolrych M, Hill R. Unintended pregnancies with the etonogestrel implant (Implanon): a case series from postmarketing experience in Australia. Contraception 2005; 71: 306– 308. 125 Davies GC, Feng LX, Newton JR, et al . Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel. Contraception 1993; 47: 251– 261. 126 Edwards JE, Moore A. Implanon. A review of clinical studies. Br J Fam Plann 1999; 24: 3– 16. 127 Bitzer J, Tschudin S, Alder J. Acceptability and side-effects of Implanon in Switzerland: a retrospective study by the Implanon Swiss Study Group. Eur J Contracept Reprod Health Care 2004; 9: 278– 284. 128 Funk S, Miller MM, Mishell DR Jr, et al . Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005; 71: 319– 326. 129 Hohmann H, Creinin MD. The contraceptive implant. Clin Obstet Gynecol 2007; 50: 907– 917. 130 Taneepanichskul S, Reinprayoon D, Thaithumyanon P, et al . Effects of the etonogestrel-releasing implant Implanon and a nonmedicated intrauterine device on the growth of breast-fed infants. Contraception 2006; 73: 368– 371. 131 Huber J. Pharmacokinetics of Implanon. An integrated analysis. Contraception 1998; 58: S85– S90. 132 Kiriwat O, Patanayindee A, Koetsawang S et al . A 4-year pilot study on the efficacy and safety of Implanon, a single rod hormonal contraceptive implant, in healthy women in Thailand. Eur J Contracept Reprod Health Care 1998; 3: 85– 91. 133 Peterson HB, Curtis KM. Clinical practice. Long-acting methods of contraception. N Engl J Med 2005; 353: 2169– 2175. 134 Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol 1999; 181: 1263– 1269. 135 Mishell DR Jr. Intrauterine devices: mechanisms of action, safety, and efficacy. Contraception 1998: S45– 53. 136 Chiou CF, Trussell J, Reyes E, et al . Economic analysis of contraceptives for women. Contraception 2003; 68: 3– 10. 137 Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol Surv 2002; 57: 120– 128. 138 Gardner FJ, Konje JC, Abrams KR, et al . Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet 2000; 356: 1711– 1717. 139 Stewart A, Cummins C, Gold L, Jordan R, et al . The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review. Br J Obstet Gynaecol 2001; 108: 74– 86. 140 Bilian X. Intrauterine devices. Best Pract Res Clin Obstet Gynaecol 2002; 16: 155– 168. 141 Grimes DA. Intrauterine devices. In: Hatcher RA, Trussell J, Stewart F, et al . Contraceptive Technology, 18th revised edn. New York, NY: Ardent Media, 2004. 142 Zhang J, Feldblum PJ, Chi IC, et al . Risk factors for copper T IUD expulsion: an epidemiologic analysis. Contraception 1992; 46: 427– 433. 143 Harrison-Woolrych M, Ashton J, Coulter D. Uterine perforation on intrauterine device insertion: is the incidence higher than previously reported? Contraception 2003; 67: 53– 56. 144 Ory HW. Ectopic pregnancy and intrauterine contraceptive devices: new perspectives. The Women's Health Study. Obstet Gynecol 1981; 57: 137– 144. 145 Franks AL, Beral V, Cates W Jr, et al . Contraception and ectopic pregnancy risk. Am J Obstet Gynecol 1990; 163: 1120– 1123. 146 Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet 2000; 356: 1013– 1019. 147 Grimes DA, Schulz KF. Prophylactic antibiotics for intrauterine device insertion: a metaanalysis of the randomized controlled trials. Contraception 1999; 60: 57– 63. 148 Mohllajee AP, Curtis KM, Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception 2006; 73: 145– 153. 149 IUDs – an update. Popul Rep B 1995; 6: 1– 35. 150 Forrest JD. U.S. women's perceptions of and attitudes about the IUD. Obstet Gynecol Surv 1996; 51: S30– S34. 151 Kaunitz AM. Beyond the pill: new data and options in hormonal and intrauterine contraception. Am J Obstet Gynecol 2005; 192: 998– 1004. 152 Ubeda A, Labastida R, Dexeus S. Essure: a new device for hysteroscopic tubal sterilization in an outpatient setting. Fertil Steril 2004; 82: 196– 199. 153 Pollack AE, Carignan CS, Jacobstein R. Female and male sterilization. In: Hatcher RA, Trussell J, Stewart F, et al. Contraceptive Technology, 18th revised edn. New York, NY: Ardent Media, 2004. 154 Escobedo LG, Peterson HB, Grubb GS, et al . Case-fatality rates for tubal sterilization in U.S. hospitals: 1979 to 1980. Am J Obstet Gynecol 1989; 160: 147– 150. 155 Hamilton BE, Martin JA, Sutton PD. Centers for Disease Control and Prevention, National Center for Health Statistics. Births: preliminary data for 2003. Natl Vital Stat Rep 2004; 23: 53: 1– 17. 156 Curtis KM, Mohllajee AP, Peterson HB. Regret following female sterilization at a young age: a systematic review. Contraception 2006; 73: 205– 210. 157 Peterson HB, Xia Z, Hughes JM, et al . The risk of ectopic pregnancy after tubal sterilization. N Engl J Med 1997; 336: 762– 767. 158 Cevrioglu AS, Degirmenci B, Acar M, et al . Examination of changes caused by tubal sterilization in ovarian hormone secretion and uterine and ovarian artery blood flow rates. Contraception 2004; 70: 467– 473. 159 Peterson HB, Jeng G, Folger SG, et al . The risk of menstrual abnormalities after tubal sterilization. N Engl J Med 2000; 343: 1681– 1687. 160 Costello C, Hillis SD, Marchbanks PA, et al . The effect of interval tubal sterilization on sexual interest and pleasure. Obstet Gynecol 2002; 100: 511– 517. 161 Trussell J, Leveque JA, Koenig JD, et al . The economic value of contraception: a comparison of 15 methods. Am J Public Health 1995; 85: 494– 503. 162 Cox B, Sneyd MJ, Paul C, et al . Vasectomy and risk of prostate cancer. J Am Med Assoc 2002; 287: 3110– 3115. 163 Speizer IS, Santelli JS, Afable-Munsuz A, et al . Measuring factors underlying intendedness of women's first and later pregnancies. Perspect Sex Reprod Health 2004; 36: 198– 205. 164 Henshaw SK. Unintended pregnancy in the United States. Fam Plann Perspect 1998; 30: 24– 29. 165 Anonymous. Consensus statement on emergency contraception. Contraception 1995; 52: 211– 213. 166 Yuzpe AA, Thurlow HJ, Ramzy I, et al . Post coital contraception – a pilot study. J Reprod Med 1974; 13: 53– 58. 167 Ellertson C. History and efficacy of emergency contraception: beyond Coca-Cola. Fam Plann Perspect 1996; 28: 44– 48. 168 Trussell J, Rodriguez G, Ellertson C. Updated estimates of the effectiveness of the Yuzpe regimen of emergency contraception. Contraception 1999; 59: 147– 151. 169 Piaggio G, Von Hertzen H, Grimes DA, et al . Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 1999; 353: 721. 170 Ellertson C, Evans M, Ferden S, et al . Extending the time limit for starting the Yuzpe regimen of emergency contraception to 120 h. Obstet Gynecol 2003; 101: 1168– 1171. 171 Croxatto HB, Devoto L, Durand M, et al . Mechanism of action of hormonal preparations used for emergency contraception: a review of the literature. Contraception 2001; 63: 111– 121. 172 Glasier A. Emergency postcoital contraception. N Engl J Med 1997; 337: 1058– 1064. 173 Food and Drug Administration. Prescription drug products: certain combined oral contraceptives for use as postcoital emergency contraception. Fed Regist 1997; 62: 8610– 8612. 174 Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet 1998; 352: 428– 433. 175 Weismiller DG. Emergency contraception. Am Fam Physician 2004; 70: 707– 714. 176 World Health Organization (WHO). Family Planning and Population. Emergency Contraception: a Guide for Service Delivery. Geneva: WHO, 1998. URL http://www.cecinfo.org/files/Medical-Service-Delivery-Gdelines.pdf [accessed on 3 June 2006]. 177 Croxatto HB, Ortiz ME, Muller AL. Mechanisms of action of emergency contraception. Steroids 2003; 68: 1095– 1098. 178 Food and Drug Administration. FDA approves over-the-counter access for plan B for women 18 and older. Prescription remains required for those 17 and under. FDA News 24 August 2006. URL http://www.fda.gov/bbs/topics/NEWS/2006/NEW01436.html [last accessed 11 January 2009]. 179 Trussell J, Stewart F, Raymond E. Emergency Contraception: A Cost-Effective Approach to Preventing Unintended Pregnancy. URL http://ec.princeton.edu/references/EC-review.pdf [accessed on 4 July 2008]. 180 Trussell J, Ellertson C, Stewart F, et al . The role of emergency contraception. Am J Obstet Gynecol 2004; 190: S30– S38. 181 Spitz IM, Bardin CW, Benton L, et al . Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med 1998; 338: 1241– 1247. 182 Moreau C, Cleland K, Trussel J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception 2007; 76: 267– 272. Citing Literature Volume48, Issue8August 2009Pages 795-814 ReferencesRelatedInformation
Referência(s)